Insider · CIK 0001770465
Leslie J. Williams
Files at OCUL (OCULAR THERAPEUTIX, INC). First filing -, latest -.
In brief
Leslie J. Williams files SEC Form 4 as director at OCUL (OCULAR THERAPEUTIX, INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Leslie J. Williams has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 65,433 | Jun 12, 2026 |
| Jun 10, 2026 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 12, 2026 |
| Jun 11, 2025 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 51,433 | Jun 13, 2025 |
| Jun 11, 2025 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 13, 2025 |
Questions about Leslie J. Williams
Answered from the filings on this page, as of the latest one.
Is Leslie J. Williams buying or selling?
Leslie J. Williams has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Leslie J. Williams's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Leslie J. Williams has 0.
Where does Leslie J. Williams file Form 4?
Leslie J. Williams has filed Form 4 at OCUL (OCULAR THERAPEUTIX, INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.